Rapt Therapeutics (RAPT) to Release Earnings on Thursday

Rapt Therapeutics (NASDAQ:RAPT) is projected to announce its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.92) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 13, 2026 at 10:30 AM ET.

Rapt Therapeutics Price Performance

RAPT opened at $58.02 on Tuesday. The business has a 50 day moving average price of $48.15 and a two-hundred day moving average price of $33.36. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -5.25 and a beta of 0.49. Rapt Therapeutics has a 1-year low of $5.67 and a 1-year high of $58.02.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Orbimed Advisors LLC raised its holdings in shares of Rapt Therapeutics by 51.2% during the fourth quarter. Orbimed Advisors LLC now owns 1,642,891 shares of the company’s stock valued at $55,645,000 after acquiring an additional 556,273 shares during the period. RTW Investments LP grew its position in Rapt Therapeutics by 11.3% during the 4th quarter. RTW Investments LP now owns 1,637,165 shares of the company’s stock worth $55,451,000 after purchasing an additional 166,666 shares in the last quarter. Siren L.L.C. raised its stake in Rapt Therapeutics by 136.9% during the 4th quarter. Siren L.L.C. now owns 1,375,000 shares of the company’s stock valued at $46,571,000 after purchasing an additional 794,534 shares during the period. Braidwell LP acquired a new stake in Rapt Therapeutics during the 4th quarter valued at $31,489,000. Finally, Nantahala Capital Management LLC lifted its holdings in shares of Rapt Therapeutics by 21.0% in the fourth quarter. Nantahala Capital Management LLC now owns 754,153 shares of the company’s stock valued at $25,543,000 after purchasing an additional 130,871 shares in the last quarter. 99.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RAPT has been the subject of several research analyst reports. Wells Fargo & Company lowered Rapt Therapeutics from an “overweight” rating to an “equal weight” rating and set a $58.00 price objective for the company. in a report on Tuesday, January 20th. Guggenheim downgraded shares of Rapt Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, January 20th. HC Wainwright lowered shares of Rapt Therapeutics from a “buy” rating to a “neutral” rating and set a $58.00 price objective for the company. in a research report on Tuesday, January 20th. Lifesci Capital cut shares of Rapt Therapeutics from an “outperform” rating to a “hold” rating in a research note on Tuesday, January 20th. Finally, TD Cowen lowered shares of Rapt Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $48.44.

About Rapt Therapeutics

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.